GLP-1 maintenance phase: what the science says about stopping

What did @glowwithtae actually say?

The creator says she lost "a little under 40" pounds in three months on a GLP-1, has been in maintenance for five months, and now "micro-doses" her GLP-1 specifically because she has PCOS. She claims this lower dose still delivers "all the same benefits, just at a different amount." That last part is where things get complicated.

To her credit, she's not selling a transformation fantasy. She's explicitly saying maintenance is hard work, not a passive state. That's an honest framing that a lot of GLP-1 content skips entirely. But the claim that microdosing delivers equivalent benefits to a therapeutic dose deserves more scrutiny than she gave it.

Does the science back this up?

On the PCOS angle, she's on solid ground. GLP-1 receptor agonists have real, studied benefits for people with PCOS beyond weight loss alone. A 2022 meta-analysis by Tong et al. in Frontiers in Endocrinology found semaglutide improved menstrual regularity, reduced androgen levels, and improved insulin sensitivity in women with PCOS. So continuing a GLP-1 for PCOS symptom management after reaching a weight goal is clinically reasonable.

Where the science gets murkier is the "microdosing" claim. There is no peer-reviewed literature establishing a standardized microdosing protocol for GLP-1 agonists in maintenance. The STEP trials (Wilding et al., 2021, NEJM) used fixed therapeutic doses. The SURMOUNT trials for tirzepatide showed dose-dependent effects, meaning lower doses produced less benefit. Claiming equivalent outcomes at sub-therapeutic doses isn't supported by current evidence.

What did they get wrong (or right)?

She got the PCOS rationale right. There's legitimate clinical logic for staying on a GLP-1 after weight loss if PCOS symptoms were a primary driver. That's not misinformation, that's a real therapeutic consideration.

What she got wrong, or at least oversimplified, is the phrase "all the same benefits, just at a different amount." That framing implies dose doesn't meaningfully change outcomes. It does. GLP-1 agonists are dose-dependent drugs. A sub-therapeutic dose may maintain some benefits, particularly metabolic ones, but the evidence base for equivalent efficacy at lower doses simply doesn't exist yet. Saying you get "all the same benefits" at a microdose isn't accurate, and it could mislead viewers into thinking they can arbitrarily reduce their dose without tradeoffs.

Her weight loss numbers, roughly 40 pounds in three months, are at the high end but not impossible for someone with significant starting weight and good medication response. She doesn't specify her starting weight, so this is unverifiable rather than implausible.

What should you actually know?

GLP-1 maintenance is an active, under-discussed phase of treatment. The STEP 4 trial (Rubino et al., 2021, NEJM) showed that people who stopped semaglutide after weight loss regained about two-thirds of their lost weight within a year. That data supports staying on medication through maintenance, which she is doing.

But "maintenance mode" on a GLP-1 is not a standardized medical category. How much drug, at what interval, for how long, is a clinical decision that depends on individual metabolic response, comorbidities like PCOS, and prescriber judgment. Viewers should not take this video as a template for self-adjusting their dose.

• GLP-1s for PCOS: real evidence, reasonable ongoing use
• Microdosing for equivalent benefits: not supported by current trial data
• Maintenance weight regain risk is real and well-documented
• Continued prescriber involvement matters, especially when adjusting dose

The bottom line

This video is more honest than most GLP-1 content on TikTok. She's not promising effortless results or pushing extreme doses. But the claim that microdosing delivers the same benefits as therapeutic dosing is not backed by evidence, and that framing could give viewers a false sense of flexibility around their own medication decisions. The PCOS rationale is legitimate. The dose equivalency claim is not.